KUALA LUMPUR: CIMB Equities Research has started coverage of Hovid with an Outperform call and a target price of 43 sen, based on sum-of-parts valuation.
It said on Wednesday the re-rating catalysts could come from increased product registrations in its export markets and strong earnings growth.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
